Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:21:33.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC, as part of a phase II trial for Small Cell Lung Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:48.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed eligibility criteria for participants, including health conditions and prior treatments, for a clinical study on extensive small cell lung cancer (SCLC). The new criteria specify histological or cytological confirmation of SCLC and other health requirements for inclusion.
    Difference
    44%
    Check dated 2024-05-22T21:28:09.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:58:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.